Frontier Medicines to Present Preclinical FMC-242 Data at Cancer Symposium
The company says preclinical data showed enhanced anti-tumor activity and tumor regression with FMC-242.
Related stories
Array Technologies to Merge With Shoals in an All-Stock Deal
Array Technologies and Shoals will combine in an all-stock transaction.
M impact | EQUITY | Nov 04, 2026, 02:21 PM UTC
Option Care Health Reports Q3 Earnings, Revenue Rise and Withdraws Guidance
Option Care Health reported higher Q3 adjusted earnings and revenue and withdrew guidance due to a pending merger.
M impact | EQUITY | Nov 04, 2026, 02:09 PM UTC
Burjeel Holdings and Burjeel Sukuk report third-quarter results
M impact | EQUITY | Nov 04, 2026, 02:09 PM UTC
Solstice Raises Annual Outlook as AI Demand Drives Quarterly Results Above Expectations
Solstice raised its annual forecasts, citing AI-related demand and quarterly results above expectations.
M impact | EQUITY | Nov 04, 2026, 02:09 PM UTC
Alphabet Backs TeraWulf Credit for Anthropic Data Center Project
TeraWulf receives credit backing from Alphabet for its data center project for Anthropic.
M impact | EQUITY | Nov 04, 2026, 02:08 PM UTC
Vivakor Highlights Potential Annual Service Revenue Above $2 Million
Direct Midstream’s conditional agreement to operate 52 New Mexico wells could generate more than $2 million in annual service revenue at targeted operating levels, subject to final
M impact | EQUITY | Nov 04, 2026, 02:08 PM UTC